Preclinical Trial-on-Chip Pediatric Oncology Model Customization Service for Neuroblastoma CAR-T

Online Inquiry

Background Service What we can offer Workflow HighlightsFAQs Contact

Creative Biolabs provides a Preclinical Trial-on-Chip Pediatric Oncology Model Customization Service that enables the validation of therapeutic efficacy and safety in high-risk neuroblastoma. Our service addresses challenges such as limited drug penetration across the blood-brain barrier and the inability of animal models to accurately predict human toxicities. By integrating patient-derived tumor explants and supporting real-time visualization of T-cell trafficking, we deliver human-relevant data to de-risk and accelerate the development of CAR-T therapies.

Introduction

Microphysiological tumor-on-chip systems have demonstrated improved prediction of immune-cell trafficking, therapeutic response, and microenvironment-driven resistance compared with conventional 2D culture and simplified animal models. Neuroblastoma, characterized by heterogeneous antigen expression and complex stromal and vascular barriers, particularly benefits from 3D perfused platforms. Integrated tumor vascular immune chip models support more clinically relevant CAR-T screening and mechanism-oriented optimization for pediatric solid tumors.

Targets in neuroblastoma for CAR T-cell immunotherapy. (OA Literature) Fig.1 Molecular targets for CAR T-cell therapy in neuroblastoma.¹

Service

Our customization service is designed to bridge the gap between simple in vitro assays and complex human clinical trials. We provide a platform that recapitulates the "holistic journey" of a CAR-T cell, from vascular adhesion to deep tumor infiltration, enabling you to observe exactly where a candidate therapy succeeds or fails.

Key Problem-Solving Capabilities:

TME Recapitulation: We build a living tumor microenvironment (TME), including vascular endothelium, stromal fibroblasts, and extracellular matrix (ECM), to study physical barriers to T-cell entry.
Target Validation: Test next-generation targets in models with human-level antigen density.
Combination Screening: Evaluate the synergy of CAR-T with "resistance breakers" or tumor-associated macrophage (TAM) depleting agents.

Discover How We Can Help - Request a Consultation to design a chip model.

What We Can Offer

Analysis Preclinical Trial-on-Chip Pediatric Oncology Model Customization. (Creative Biolabs Original)

Our Workflow

Required Starting Materials: To initiate the customization, clients typically provide target antigen specifications, specific CAR-T cell constructs (or sequences for our team to manufacture), and desired tumor cell lines or primary patient-derived xenograft samples.

Workflow of Preclinical Trial-on-Chip Pediatric Oncology Model Customization. (Creative Biolabs Original)

Final Deliverables: Clients receive comprehensive data packages including high-resolution 3D videos of T-cell trafficking, quantitative reports on tumor regression/cytokine release, and transcriptomic profiling of tumor-infiltrating lymphocytes.

Our Advantages

Fully customized neuroblastoma-on-chip models tailored to your CAR-T design, target antigen profile, and pediatric tumor biology, provided by Creative Biolabs.
One-stop microphysiological modeling service covering chip design, 3D tumor reconstruction, immune integration, dynamic perfusion, and data analysis.
Neuroblastoma-specific microenvironment reconstruction, including stromal components, matrix density tuning, hypoxia modules, and vascular barriers to realistically reflect pediatric solid tumor architecture.
Parallel evaluation of multiple CAR-T candidates, dosing regimens, and administration strategies within the same standardized chip platform.

FAQs

Q1: How does this chip model compare to traditional PDX animal models for neuroblastoma?

A1: While animal models are useful, they often fail to replicate human-specific immune signaling. Our chip uses 100% human cells, enabling a more accurate assessment of T-cell trafficking and on-target/off-tumor toxicity, which is often "lost in translation" in murine systems.

Q2: Can we use our own patient-derived tumor samples for the chip customization?

A2: Absolutely. Our service incorporates unmodified patient explants, spheroids, or organoids into our vascularized beds, providing a personalized "trial-on-a-chip" to evaluate construct efficacy against a specific patient's TME.

Q3: What parameters can you measure to evaluate CAR-T "exhaustion" on the chip?

A3: We utilize real-time imaging for kinetic killing analysis to look for markers of exhaustion or mitochondrial dysfunction. We can also measure cytokine profiles from the chip effluent to assess functional potency over time.

Q4: Is the model compatible with high-throughput drug screening?

A4: Yes. We have reconfigured our systems into multi-well array formats that allow for simultaneous testing of various drug concentrations or T-cell to tumor cell ratios, ensuring you can optimize your therapeutic window efficiently.

Partner with Us

Creative Biolabs provides a comprehensive Preclinical Trial-on-Chip Pediatric Oncology Model Customization Service specifically tailored for Neuroblastoma CAR-T development. By combining microfluidic vascularization with patient-derived samples and multi-omic insights, we provide a high-fidelity surrogate for human clinical trials, enabling faster, safer, and more effective drug discovery. Ready to advance your pediatric oncology project? Our team of elite scientists is available to discuss your specific requirements and design a custom chip solution. Contact Our Team for More Information and to Discuss Your Project.

Reference

Richards, Rebecca M et al. "CAR T Cell Therapy for Neuroblastoma." Frontiers in immunology vol. 9 2380. 16 Oct. 2018. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2018.02380

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.